CareDx (CDNA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

CareDx

NasdaqGM•Healthcare•Diagnostics & Research

$70.53+1.43(0.02%)Pre-market

Market Cap

$4.56B

P/E

35.4x

P/S

9.2x

P/B

9.7x

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

How this company scores

ExcellentMetricSide Score: 80/100

Strongest: Growth (25/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability22/25

Growth25/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality18/25

Strengths

Growing revenueRising free cash flowStrong marginsHigh ROE

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 35.4x5y range 12.8x – 35.4x

Currently above its 6-quarter median.

P/S · 9.2x5y range 1.3x – 9.2x

Currently above its 20-quarter median.

P/B · 9.7x5y range 1.0x – 9.7x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

FCF consistently trails net income (avg 2.5x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $4.56B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $497.40M
Q. Revenue: $139.36M
TTM EBITDA: $141.82M
TTM Op. Income: $116.49M
Q. Op. Income: $8.11M
TTM Net Income: $128.63M
Q. Net Income: $19.29M
EPS: $0.37
Shares Out.: $52.12M

$497.40M in TTM revenue grew 38.9% YoY, reaching $139.36M last quarter. TTM EBITDA of $141.82M and TTM operating income of $116.49M show growth is flowing through to the bottom line. TTM net income of $128.63M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 11.0%
Op. Margin: 5.8%
Net Margin: 13.8%

Op. margin of 5.8% is up 6.1% YoY — cost efficiency is improving. Net margin at 13.8% Over the past year, operating margin is up 2467% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 35.4x
P/S Ratio: 9.2x
P/B Ratio: 9.7x

At 35.4x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 9.2x and P/B of 9.7x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 6 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $641.46M
Cash: $250.48M
Long-Term Debt: N/A
Book Value: $467.46M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $12.72M
TTM Free Cash Flow: $61.73M
FCF Margin: 12.4%
FCF / Net Income: 0.5

TTM FCF of $61.73M on $12.72M in operating cash flow. The FCF / Net Income ratio of 0.5x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is up 45% — a weakening trend.